FAQs

About 15% of Parkinson’s patients have a family history of the disease. These cases, referred to as familial Parkinson’s, typically are caused by mutations in a disease-associated gene that can be passed by parents to their biological children. For most people with Parkinson’s, the disease does not run in…

Parkinson’s disease, also called primary parkinsonism, is the most common form of parkinsonism. Parkinson’s disease accounts for roughly 80% of all cases where people develop Parkinson’s-like symptoms. Other cases mainly are caused by atypical or secondary forms of parkinsonism, where symptoms develop as a byproduct of other health conditions.

Parkinson’s disease manifests with a lot of variability, so that even people with the same Parkinson’s subtype can have considerably different experiences and life expectancies. Parkinson’s disease itself, also known as primary parkinsonism, usually is milder and progresses more slowly than the rarer atypical forms of parkinsonism.

Parkinson’s disease is highly variable, and it doesn’t affect any two people in the same way. Even among people with the same subtype of Parkinson’s, there can be variability in disease symptoms, the age at onset, and rate of disease progression. In general, atypical forms of parkinsonism progress more…

Parkinson’s disease refers to a specific neurological condition caused by the progressive death and dysfunction of dopamine-making cells in the brain, leading to characteristic motor symptoms including tremor, rigidity and bradykinesia or slowed movements. There also are several forms of atypical and secondary parkinsonism, where other…

While clinical trials have not reported weight gain as a side effect of Tasmar, hair loss has been seen among a very small percentage of patients treated with Tasmar. Additionally, some individuals taking levodopa-based medications have reported experiencing hair loss and weight gain. If patients notice hair loss or weight…

Based on clinical trial data, benefis from Tasmar may be observed as early as six weeks after starting treatment. In a trial involving patients without motor fluctuations, significant improvements in activities of daily living were seen after six weeks, which were sustained for at least one year, while reductions in…

When taking Tasmar, individuals may experience intense drowsiness or unexpected episodes of falling asleep during their daily activities. To ensure safety, patients should avoid driving or participating in any potentially dangerous tasks until they understand how the medication affects them. If any of these adverse side effects occur, it is…

It remains uncertain whether Tasmar is safe for use during pregnancy. While animal studies suggest it may cause harm to a developing fetus, there is a lack of clinical data examining its effects in pregnant patients. If patients are planning to become pregnant while on Tasmar, it is recommended they…

The U.S. Food and Drug Administration approved Tasmar in January 1998 as an add-on treatment to ease symptoms in Parkinson’s patients receiving levodopa and carbidopa. However, due to an increased risk of liver failure, the therapy is only recommended for patients experiencing motor fluctuations and who failed to respond…